Lutetium-177 DOTA-Zoledronate - ITM Medical Isotopes GmbH
Alternative Names: DP-4411; ITM-41; n.c.a Lutetium-177 DOTA-Zoledronate; n.c.a. 177Lu-DOTA-Zoledronate; n.c.a. 177Lu-ZoledronateLatest Information Update: 28 Nov 2024
At a glance
- Originator Johannes Gutenberg-University Mainz
- Developer ITM Medical Isotopes GmbH
- Class Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bone metastases; Osteosarcoma
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for phase-I development in Bone metastases in Germany (Parenteral)
- 28 Nov 2024 No recent reports of development identified for phase-I development in Osteosarcoma in Germany (Parenteral)
- 27 Dec 2021 Lutetium- 177 DOTA-Zoledronate licensed to Grand Pharmaceutical in mainland China, Hong Kong, Macau and Taiwan